Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The RIDD trial has completed recruitment and will now begin its follow up phase.

Ridd

The RIDD trial aims to test whether the progression of Dupuytren’s disease can be halted or slowed by treatment with anti-TNF injection. Currently, Dupuytren’s disease is left to progress until the finger deformity is severe enough to warrant a surgical procedure in hospital. If successful, anti-TNF treatment would prevent loss of hand function and the need for surgery, and would allow patients to be treated conveniently and quickly.

We are delighted that recruitment to the RIDD trial (Part 2) is now complete.

A total of 181 participants have been recruited from the 3 centres running the trial – Oxford, Edinburgh and Groningen in The Netherlands.

The Trial Management Group would like to thank the staff at these centres for their work in achieving this important milestone as well as all the patients who have joined the trial.

For updates on the trial see: http://ridd.octru.ox.ac.uk/